Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
Abendroth
D
D
Sandoz AG, Nürnberg.
Buchholz
B
B
Land
W
W
May
G
G
Wiesel
M
M
Färber
L
L
Korn
A
A
Maibücher
A
A
D000284:Administration, Oral; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005858:Germany; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D013997:Time Factors; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000097:blood
D007166:Immunosuppressive Agents; D014527:Uric Acid; D016572:Cyclosporine; D014508:Urea; D003404:Creatinine